Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

Vir Biotechnology, Inc. ( NASDAQ: VIR) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET ...

These problems can be best addressed by systematic studies of antigen three-dimensional structure and further ... the production of a recombinant hepatitis B virus (HBV) vaccine 3.

Total Revenue of $426.5 Million, a 65% YoY IncreaseFY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation ...

Groundhogs serve as the best non-human model for studying the hepatitis B virus, which causes liver damage and liver ... Attach the material to the lower edge of the structure, and bury it at least 12 ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

A new study that has the potential to change the landscape of hepatitis B transmission in Africa. Researchers conducted an analysis revealing key interventions that could effectively eliminate ...

Researchers at the University of Liverpool have conducted a large-scale analysis that sheds light on the critical steps ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and ...

Maternal hepatitis C virus (HCV) RNA titer > 10⁶ International Units (IU)/mL and antepartum bleeding are key predictors of ...